Qtrex Quantum Ltd (NASDAQ:QTEX) disclosed a $10 million registered direct offering comprising 11,111,111 ordinary shares to be sold to institutional investors, including participation from an existing institutional investor and a new global institutional investor. The announcement triggered a 16% decline in the company’s shares during pre‑market trading on Thursday. The offering is slated to close on or about August 21, 2026, subject to customary closing conditions, with A.G.P./Alliance Global Partners acting as the sole placement agent. Qtrex indicated that net proceeds, after deducting placement agent fees and other estimated offering expenses, will be allocated to working capital and general corporate purposes. The company’s strategic focus remains on advancing additively manufactured electronics for quantum computing infrastructure, following its acquisition of the AME platform; it is developing high‑density, thermally optimized quantum connectivity solutions for dilution cryostats and extending AME applications to defense, aerospace, missile, space, and other mission‑critical environments. Concurrently, Qtrex is progressing its medical technology portfolio, which includes respiratory support and blood monitoring platforms, and is working to monetize certain segments of the medical business. This article was generated with AI assistance and reviewed by an editor.